Lifeloc Technologies Q3 net loss narrows as margin improves
Overview
US breathalyzer maker's Q3 net loss narrowed
Gross margin improved to 43% from 40% due to price increases, favorable product mix
SpinDetect analyzer launch delayed to Q4 2027; high R&D spend contributed to loss
Outlook
Lifeloc now expects limited commercial launch of SpinDetect in Q4 2027, delayed from Q1 2027
Lifeloc is prioritizing upgrades to core alcohol testing products to boost near-term cash flow
Result Drivers
PRICE INCREASES AND PRODUCT MIX - Co said higher prices and a favorable product mix contributed to improved gross margin
HIGH R&D SPENDING - Elevated research and development costs, mainly for SpinDetect analyzer, contributed to quarterly loss
RESOURCE REALLOCATION - Co is redirecting engineering resources to core products to generate incremental revenue and fund SpinDetect development
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.03 | ||
Q3 Net Loss | $85,000 | ||
Q3 Gross Margin | 43.00% |
Reuters Recommended Reads
Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall
Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall
Nov 13 - Tempest Therapeutics Q3 net loss per share narrows on lower R&D expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)